Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127136821 | 12713682 | 1 | I | 20160720 | 20160904 | 20160904 | PER | US-ASTRAZENECA-2016SE79976 | ASTRAZENECA | 0.00 | F | Y | 102.50000 | KG | 20160904 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127136821 | 12713682 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 22200 | 2 | MG | /wk | ||||||||
| 127136821 | 12713682 | 2 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 22200 | 2 | MG | /wk | ||||||||
| 127136821 | 12713682 | 3 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 22200 | 2 | MG | /wk | ||||||||
| 127136821 | 12713682 | 4 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 22200 | 2 | MG | /wk | ||||||||
| 127136821 | 12713682 | 5 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 22200 | 2 | MG | /wk | ||||||||
| 127136821 | 12713682 | 6 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 22200 | 2 | MG | /wk | ||||||||
| 127136821 | 12713682 | 7 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | UNKNOWN | U | 0 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||||
| 127136821 | 12713682 | 8 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | UNKNOWN | U | 0 | SOLUTION FOR INJECTION IN PRE-FILLED PEN |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127136821 | 12713682 | 1 | Type 2 diabetes mellitus |
| 127136821 | 12713682 | 2 | Blood glucose increased |
| 127136821 | 12713682 | 3 | Glycosylated haemoglobin increased |
| 127136821 | 12713682 | 4 | Type 2 diabetes mellitus |
| 127136821 | 12713682 | 5 | Blood glucose increased |
| 127136821 | 12713682 | 6 | Glycosylated haemoglobin increased |
| 127136821 | 12713682 | 7 | Type 2 diabetes mellitus |
| 127136821 | 12713682 | 8 | Type 2 diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127136821 | 12713682 | Blood glucose increased | |
| 127136821 | 12713682 | Corrective lens user | |
| 127136821 | 12713682 | Diarrhoea | |
| 127136821 | 12713682 | Drug dose omission | |
| 127136821 | 12713682 | Faeces discoloured | |
| 127136821 | 12713682 | Haematochezia | |
| 127136821 | 12713682 | Malaise | |
| 127136821 | 12713682 | Memory impairment | |
| 127136821 | 12713682 | Mucous stools | |
| 127136821 | 12713682 | Nausea | |
| 127136821 | 12713682 | Vomiting projectile |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127136821 | 12713682 | 1 | 201604 | 0 | ||
| 127136821 | 12713682 | 2 | 201604 | 0 | ||
| 127136821 | 12713682 | 3 | 201604 | 0 |